Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2/3. fázis

TAP-TAU

A legfontosabb adatok

Ki végzi
Amsterdam UMC
Hol
Hollandia6 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Toboroz
Fázis
2/3. fázis
Résztvevők
360 fő, tervezett
Kezdés
2024. okt. 10.
Várható befejezés
2026. dec. 1.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. március 18.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for memory clinic patients with mild memory or thinking problems or mild dementia. Their diagnosis must still be unclear after routine tests, and Alzheimer's disease must be one possible cause.

Életkor
The criteria say 50 years or older; the record's minimum age field says 65 Years.
Nem
All sexes can join.
A betegség stádiuma
Early stage (mild cognitive impairment, CDR score 0.5) or mild dementia (CDR score 1). The doctors must be less than 85% sure of the diagnosis. Reasons can be suspected mixed causes, unusual symptoms, or unclear results from other tests like MRI or spinal fluid (CSF).
Korábbi kezelés
People must have finished routine work-up, with at least basic memory tests and an MRI scan with a 3DT1 sequence. Tau PET participants cannot join if they were ever treated with an anti-amyloid drug or tau agent.

A részvétel fő kizáró okai

  • Normal memory and thinking (CDR 0) or advanced dementia (CDR above 1).
  • Major stroke, mass or other brain changes on MRI that could affect symptoms or the PET scan.
  • Other serious diseases of the heart, blood, liver, kidneys, lungs, mind or other organs, as judged by the lead researcher.
  • For tau PET: pregnancy, breastfeeding, no reliable birth control, or a severe drug allergy.
  • For tau PET: a recent radioactive tracer injection, or yearly research radiation above 11.3 mSv for females and 15.3 mSv for males.

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients 50 years or older
  • Prodromal (i.e. MCI) stage, in which individuals have subjective and/or objective cognitive impairment and a CDR score of 0.5 or mild dementia stage, in which individuals have a CDR score of 1
  • Completed routine work-up including at least basic cognitive screening tests and MRI scanning with a 3DT1 sequence
  • After routine dementia screening, there is substantial diagnostic uncertainty (<85%) due to i) suspicion of mixed pathology, ii) presence of an atypical clinical presentation, and/or iii) conflicting/inconclusive information from other diagnostic tests like MRI or CSF. AD is in the differential diagnosis
  • Subjects must, in the opinion of the attending neurologist be able to tolerate study procedures (only for the tau PET participants) and be competent to make a well-informed decision to participate in this study

Ki nem vehet részt

  • Has ever been treated with an anti-amyloid drug or tau agent (only for tau PET participants)
  • Has been injected with a previously administered radiopharmaceutical within 6 terminal half-lives or when total yearly radiation exposure for research exceeds 11.3 mSv for females and 15.3 mSv for males. (only for tau PET participants)
  • Cognitively normal (defined as no objective cognitive deficits at neuropsychological testing and a Clinical Dementia rating scale (CDR) score of 0) or advanced dementia stage (defined as CDR > 1)
  • Has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with the clinical presentation and/or interpretation of PET scan
  • Has a relevant history of severe drug allergy or hypersensitivity. Relevant severe drug allergies should be determined by the locally appointed coordinating researcher (only for tau PET participants)
  • History of any clinically significant cardiovascular, endocrinology, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic (with the exception of AD), psychiatric, renal or other major disease, as determined by the principal investigator
  • Is a woman of childbearing potential who is not surgically sterile, not refraining from sexual activity or not using reliable methods for contraception. Women of childbearing potential must confirm not to be pregnant or breast feeding at screening; (only for tau PET participants)
  • Is a member of the study team, an employee of the department of Radiology and Nuclear medicine or the department of Neurology in any of the sites or is related to an employee of the department of Radiology and Nuclear medicine or the department of Neurology in any of the sites

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To assess the value of tau PET as a diagnostic tool in clinical practice in order to improve diagnostic accuracy, patient management and patient wellbeing.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
The clinical value of tau PET in the memory clinic (TAP-TAU)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. március 18.